ArticleNature nanotechnology2025
Ferumoxytol promotes haematopoietic stem cell post-injury regeneration as a reactive oxygen species scavenger.
Article in Nature nanotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Can nanozymes make the leap to the clinic? Advances, hurdles, and prospects.Trends in biotechnology · 2026Review
- TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia.Nature cancer · 2026Article
- Ferumoxytol enhances NF-κB-responsive GBA-targeted ferroptosis gene therapy in acute myeloid leukemia.Journal of nanobiotechnology · 2026Article
- Ferrostatin-1 and hinokitiol supplementation enhance human hematopoietic stem cell expansion in a chemically defined medium.Molecular therapy. Advances · 2026Article
- Ferumoxytol triggers cancer ferroptosis via an NF-κB-driven IRONKILL mechanism.Cancer biology & medicine · 2026Article
- Transient mechanical activation of the Piezo1 channel facilitates ex vivo expansion of hematopoietic stem cells.Cell research · 2026Article
- Copper-ion releasing LDH nanosheets-hydrogel synergistically enhance subchondral bone repair.Regenerative biomaterials · 2026Article
- An organolutetium nanosensitizer synergizes with PARP inhibition to unleash STING-mediated immunity for low-dose radioimmunotherapy.Theranostics · 2026Article
- Emerging nanoparticles that target and eliminate cancer stem cells.Nanomedicine (London, England) · 2025Review
- Nanozymes Targeting Redox Imbalance: A Novel Weapon for Immunomodulation and Organ Protection in Sepsis.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Under stress conditions, such as ex vivo culture, chemotherapy, irradiation and infection, haematopoietic stem cells (HSCs) actively divide to maintain blood cell production. This process leads to production of reactive oxygen species (ROS) that causes HSC exhaustion and haematopoietic failure. Here we show that ferumoxytol (FMT; Feraheme), a Food and Drug Administration-approved nanodrug, is a powerful ROS scavenger capable of relieving ROS in stressed HSCs, facilitating their post-injury regeneration. Mechanistically, the catalase-like activity of FMT reduces intracellular levels of H
Indexed as
Identifiers
40269251What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.